BioCryst Pharmaceuticals, Inc. (BCRX) announced Monday that the Public Health Institute (ISP) of Chile has granted marketing authorization for oral, once-daily ORLADEYO (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in patients 12 years of age or older.
Ford (F) reiterated its expectations for full-year 2023 adjusted EBIT of $9 billion to $11 billion and adjusted free cash flow of about $6 billion. The company continues to anticipate EBIT of about $7 billion for Ford Blue, up modestly from 2022, and approaching $6 billion for Ford Pro, nearly double last year, and a full-year loss of about $3 billion for the startup Ford Model e.
Consumers in the Netherlands continued to remain pessimistic in May as they became more negative about the economic climate, data from the Central Bureau of Statistics showed on Monday.
IDEAYA Biosciences, Inc. (IDYA) announced the FDA has completed its review of the Amgen-sponsored Investigational New Drug application and concluded that the proposed clinical study may proceed to evaluate IDE397 in combination with AMG 193 in solid tumors having MTAP deletion.